ZCZengke Chen

Zengke Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zengke Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Dorothy C. C. Wai

    Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

    2 shared publications
  • Gyorgy Panyi

    Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen and MTA Centre of Excellence, Hungarian Academy of Sciences, Egyetem tér 1, Debrecen H-4032, Hungary

    2 shared publications
  • Hefeng Song

    Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

    2 shared publications
  • Jinghan Qu

    Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

    2 shared publications
  • Karoline Sanches

    Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

    2 shared publications
  • Lihuan Lin

    Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

    2 shared publications

Latest Publications

  • Open Access

    Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution

    by Lihuan Lin, Thomas R. Mitchell, Karoline Sanches, Mohammad Abdallah, Yuxiang Ren, Muhammad Asim Farooq, Hefeng Song, Jinghan Qu, Zengke Chen, William De Nardo, et al.

  • Open Access

    Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution

    by Lihuan Lin, Thomas Mitchell, Karoline Sanches, Mohammad Abdallah, Yuxiang Ren, Muhammad Farooq, Hefeng Song, Jinghan Qu, Zengke Chen, William De Nardo, et al.

    Autoimmune diseases impact over 250 million people globally. Previous studies have shown that upregulation of the voltage-gated potassium channel KV1.3 in effector memory T cells is associated with the pathogenesis of a range of autoimmune diseases. HsTX1[R14A] is a 34-residue peptide that has picomolar potency and high selectivity for KV1.3, and is effective in treating a rodent model of rheumatoid arthritis. However, the short in vivo half-life of HsTX1[R14A] can be improved to enhance its potential as a therapeutic candidate. Here we explore how lipid conjugation on HsTX1[R14A] affects its circulating half-life and its distribution to key organs, tissues, and draining lymph nodes. HsTX1[R14A] was conjugated to lipids with long acyl chain (C16 and C18) for pharmacokinetic (PK) studies, and the fluorophore Cy5 was conjugated to the HsTX1[R14A] analogs for biodistribution studies. LC-MS/MS assays were developed to quantify the lipidated peptides in mouse plasma. Conjugation of palmitic and stearic acid to HsTX1[R14A] extended its exposure in plasma by 9-fold and prolonged its half-life by 2-fold after subcutaneous (SC) injection in mice. Biodistribution studies demonstrated that Cy5-labelled lipidated analogs enhance accumulation at the dosing site and draining lymph nodes at 4 h and 12 h after SC injection compared to Cy5-HsTX1[R14A]. Cy5-labelled lipidated analogues of HsTX1[R14A] also accumulated in the gastrointestinal (GI) tract more than HsTX1[R14A], while having significantly less exposure in the kidneys at 4 h and 12 h after SC administration. Thus, lipidation is a promising approach to optimize the PK, biodistribution and therapeutic potential of HsTX1[R14A].